Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells

Sliwkowski MX, 1999, Semin Oncol, 26, 60

Baselga J, 1996, J Clin Oncol, 14, 737, 10.1200/JCO.1996.14.3.737

10.1056/NEJM200103153441101

Cobleigh MA, 1999, J Clin Oncol, 17, 2639, 10.1200/JCO.1999.17.9.2639

10.1002/cncr.25120

10.1056/NEJMoa052306

10.4161/cbt.11.9.15045

Kute TE, Stehle JR. Development of trastuzumab resistance – Is it only in signaling? In: HER2 and Cancer: Mechanism, Testing and Targeted Theory. Nova Science Publishers, Inc Hauppauge, NY 2011; chapter VI;161-174.

10.1038/nrm1962

10.1038/sj.onc.1210379

10.1158/1078-0432.CCR-04-0225

10.1038/74704

10.1038/sj.bjc.6602930

10.1158/0008-5472.CAN-07-2068

10.1200/JCO.20.3.719

10.1023/A:1012999012192

10.1002/cyto.a.10095

10.1007/s00262-009-0700-0

10.1089/adt.2004.2.363

10.1021/tx049721s

10.1016/j.jim.2005.10.018

Tanner M, 2004, Mol Cancer Ther, 3, 1585, 10.1158/1535-7163.1585.3.12

10.1097/01.cad.0000236313.50833.ee

10.1158/1535-7163.MCT-06-0766

10.1158/0008-5472.CAN-07-2068

10.1089/adt.2006.4.555

10.1016/j.ijpara.2010.11.012